Company
Headquarters: Shanghai, China
Employees: 12,946
CN¥13.73 Billion
CNY as of Jan. 1, 2026
US$1.96 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Shanghai Shyndec Pharmaceutical Co., Ltd. manufactures drug preparation products in China and internationally. It focuses on anti-infection, cardiovascular and cerebrovascular, anti-tumor, metabolism, and endocrine areas. The company was founded in 1996 and is based in Shanghai, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥9.26 B |
| EBITDA | CN¥1.77 B |
| Gross Profit TTM | CN¥3.01 B |
| Profit Margin | 10.04% |
| Operating Margin | 10.61% |
| Quarterly Revenue Growth | -22.40% |
Shanghai Shyndec Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600420 wb_incandescent